
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Oct3/4 CRISPR Activation Plasmid (h) | sc-410951-ACT | 20 µg | $397.00 | |||
Oct3/4 CRISPR Activation Plasmid (h2) | sc-410951-ACT-2 | 20 µg | $397.00 |
Human POU5F1B encodes Oct3/4, a POU-domain transcription factor–related protein implicated in regulating pluripotency-associated transcriptional programs and chromatin state. Oct3/4-linked networks intersect with stemness circuitry, epigenetic remodeling, and cell fate determination processes that influence differentiation potential and self-renewal phenotypes. Dysregulated expression or copy number changes involving POU5F1B have been reported in multiple tumor contexts, where altered OCT factor activity can associate with proliferation, lineage plasticity, and transcriptional rewiring. As a result, POU5F1B is frequently studied in models of oncogenic transcription, cellular reprogramming, and developmental gene regulation.
Oct3/4 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous POU5F1B expression without altering the underlying DNA sequence.
Oct3/4 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the POU5F1B locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the POU5F1B transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Oct3/4 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native POU5F1B locus and enabling the study of Oct3/4-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Oct3/4 pathway restoration in tumor cells with silenced or reduced POU5F1B expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.